Rouse, D.J., Hirtz, D.G., Thom, E., et al. (2008) A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. The New England Journal of Medicine, 359, 895.
 Crowther, C.A., Hille, J.E., Doyle, L.W. and Haslam, R.R. (2003) Effect of magnesium sulfate given for neuroprotection before preterm birth: A randomized controlled trial. JAMA, 290, 2669-2676.
 Marret, S., Marpeau, L., Follet-Bouhamed, C., et al. (2008) Effect of magnesium sulphate on morality and neurologic morbidity of the very-preterm newborn (of less than 33 weeks) with two-year neurological outcome: Results of the prospective PREMAG trial. Gynécologie Obstétrique & Fertilité, 36, 278-288. http://dx.doi.org/10.1016/j.gyobfe.2008.01.012
 Costantine, M.M. and Weiner, S.J. (2009) Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Effects of antenatal exposure to magnesium sulfate of neuroprotection and mortality in preterm infants: A meta-analysis. Obstetrics & Gynecology, 114, 354. http://dx.doi.org/10.1097/AOG.0b013e3181ae98c2
 American College of Obstetricians and Gynecologists (2010) Magnesium sulfate before anticipated preterm birth for neuroprotection. Committee Opinion No. 455. Obstetrics & Gynecology, 115, 669-671. http://dx.doi.org/10.1097/AOG.0b013e3181d4ffa5
 Food and Drug Administration (2013) FDA recommends against prolonged use of magnesium sulfate to stop preterm labor due to bone changes in exposed babies. FDA Drug Safety Communication. Silver Springs, FDA. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM353335.pdf